Free Trial
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:IMCR

Immunocore Q3 2024 Earnings Results & Report

Immunocore logo
$27.82 -1.22 (-4.20%)
Closing price 04:00 PM Eastern
Extended Trading
$27.90 +0.07 (+0.27%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunocore beat analyst expectations on both earnings and revenue in its Q3 2024 results, released November 6, 2024. The company reported EPS of $0.17 versus the -$0.33 consensus estimate, while revenue of $80.25 million topped the $78.94 million estimate by $1.31 million. Revenue increased 23.7% year over year.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2024
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Immunocore EPS Results

Actual EPS
$0.17
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.50
One Year Ago EPS
-$0.59
EPS Beat Rate
6 of last 8 quarters

Immunocore Revenue Results

Actual Revenue
$80.25 million
Expected Revenue
$78.94 million
Beat/Miss
Beat by +$1.31 million
YoY Revenue Growth
+23.70%

Upcoming Earnings

Immunocore's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunocore's Q3 2024 Press ReleasePress Release
(8-K)
Immunocore's Q3 2024 Quarterly reportQuarterly report
(10-Q)

Immunocore Q3 2024 Earnings FAQ

Immunocore (NASDAQ:IMCR) reported earnings of $0.17 per share for Q3 2024, beating the consensus estimate of -$0.33. The report was announced on Wednesday, November 6, 2024.

Immunocore reported revenue of $80.25 million for Q3 2024, against a consensus estimate of $78.94 million.

Immunocore's next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Immunocore on the company's earnings history page.

Immunocore Earnings Headlines

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial
September 29, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4950644-immunocore-advanced-cutaneous-melanoma-data-catalysts-feels-crucial
Immunocore Holdings plc (IMCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
September 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4946193-immunocore-holdings-plc-imcr-presents-at-morgan-stanley-24th-annual-global-healthcare
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
October 13 at 1:00 AM  |  Profits Run (Ad)
Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment
September 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/immunocore-completes-enrollment-study-potential-114631684.html
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3360930/0/en/immunocore-announces-achievement-of-target-enrollment-in-registrational-tebe-am-trial-with-kimmtrak-tebentafusp-in-previously-treated-advanced-melanoma.html
Immunocore to present at upcoming investor conferences
September 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/01/3353932/0/en/immunocore-to-present-at-upcoming-investor-conferences.html
See More Immunocore Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunocore? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunocore and other key companies, straight to your email.

About Immunocore

Immunocore (NASDAQ:IMCR) Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapies designed to treat cancer and other serious diseases. Its ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and redirect the patient’s T cells to destroy those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is a bispecific TCR therapy approved in the United States and Europe for certain adults with unresectable or metastatic uveal melanoma, a rare form of eye cancer. Immunocore is also developing additional ImmTAC medicines for other solid tumors, hematologic cancers, infectious diseases and autoimmune conditions.

Founded in 2008 and headquartered in Abingdon, England, Immunocore serves international markets through its commercial and development operations in the United States and Europe, as well as through global clinical and regulatory activities. The company is led by Chief Executive Officer Bahija Jallal.

View Immunocore Profile
Earnings Tools